Ella (Ulipristal Acetate) Patent Expiration, LOE Window & CMS Spending
Ella (Ulipristal Acetate) by Laboratoire Hra: FDA Orange Book LOE 2030-06-12, 1 AB generics, $5.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Laboratoire Hra |
| FDA Application & Pathway | N022474 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-06-12 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $5.2M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $5.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |